Novai leverages its proprietary DARC (Detection of Apoptosing Retinal Cells) technology to pioneer early detection and intervention for eye and brain diseases. DARC technology uses a fluorescent dye that binds to apoptotic (dying) cells in the retina, allowing for early identification of disease activity through retinal imaging.

Novai focuses on combating blindness and disability by targeting eye diseases such as glaucoma and age-related macular degeneration, as well as brain diseases, including multiple sclerosis and Alzheimer's disease. Early detection through DARC technology can lead to timely intervention and better patient outcomes.

Novai is in the advanced stages of clinical development, having successfully completed initial trials demonstrating the efficacy of DARC technology. The next milestones include larger-scale clinical trials, regulatory approvals, and expanding partnerships with healthcare providers and research institutions to integrate DARC into standard diagnostic practices.

Novai's DARC technology offers a non-invasive, highly sensitive method for early detection of cellular apoptosis, which is a precursor to many eye and brain diseases. Unlike traditional diagnostic methods that detect disease at later stages, DARC can identify issues at a cellular level, allowing for much earlier intervention.

Novai plans to commercialize DARC technology through collaborations with ophthalmology clinics, hospitals, and research institutions. The market potential is substantial, given the prevalence of eye and brain diseases globally. By enabling early detection, DARC technology not only has the potential to improve patient outcomes but also to reduce healthcare costs associated with late-stage disease management.

Investors have the opportunity to support a pioneering medtech company that is addressing significant unmet medical needs. Investment opportunities include equity financing, strategic partnerships, and collaborative research funding. Interested investors can get involved by contacting Novai's investor relations team through the contact information provided on our website.